First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.

NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.

AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.

A look at big oncology deals since 2016 finds outright success stories hard to come by. 

Imbruvica faces challenges on multiple fronts.

Jaypirca secures a CLL label, though plans to dominate will be tempered by this market’s fast-changing nature.

A prostate cancer project licensed from Orion enters phase 3, while pivotal trials are expanded with assets originated at Kelun and Arqule.